Document Detail


Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori.
MedLine Citation:
PMID:  19142036     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Recently, the number of Helicobacter pylori isolates showing antibiotic resistance has been increasing. Rifabutin (RFB) is one of the possible candidates for H. pylori eradication. In the present study, the RFB minimum inhibitory concentrations (MICs) and the resistance-determining genes to RFB (rpoB) were examined to clarify the relationship between drug MICs, rpoB mutations, and past history of rifampicin (RFP) treatment. METHODS: The MICs of RFB and rpoB mutations were examined for 48 strains with failure of H. pylori eradication in the University Hospital and 46 isolated from patients at a specialized hospital for chronic respiratory diseases without past H. pylori eradication. Past RFP treatment was also examined. RESULTS: Eight of 94 strains showed high RFB MICs and 6 of the 8 strains showed rpoB point mutations. Although no strains showed high RFB MICs among 48 strains from the patients in the University Hospital, all 7 strains isolated from patients with past RFP treatment showed high RFB MICs (>or=0.12 mg/l). CONCLUSION: Although RFB might be a potential candidate component of a new H. pylori eradication regimen following the first- or second-line failure, it should be used after examining a past history of RFP treatment.
Authors:
Shoji Suzuki; Hidekazu Suzuki; Toshihiro Nishizawa; Fumihiko Kaneko; Sumire Ootani; Hiroe Muraoka; Yoshimasa Saito; Intetsu Kobayashi; Toshifumi Hibi
Related Documents :
7806346 - Adaptive mutation and cocolonization during helicobacter pylori infection of gnotobioti...
24254026 - Indirect thermal selection in drosophila melanogaster and adaptive consequences.
18304376 - Clostridium difficile: the increasingly difficult pathogen.
8574736 - Rationale for the choice of antibiotics for the eradication of helicobacter pylori.
1789426 - Use of a mutant strain of the cyanobacterium synechococcus r2 for the determination of ...
25249356 - Characterisation of bacterial growth and antimicrobial susceptibility patterns in canin...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-01-14
Journal Detail:
Title:  Digestion     Volume:  79     ISSN:  1421-9867     ISO Abbreviation:  Digestion     Publication Date:  2009  
Date Detail:
Created Date:  2009-03-30     Completed Date:  2009-07-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0150472     Medline TA:  Digestion     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  1-4     Citation Subset:  IM    
Affiliation:
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Bacterial Agents / pharmacology*
DNA-Directed RNA Polymerases / genetics
Drug Resistance, Bacterial / genetics*
Endoscopy, Gastrointestinal
Female
Helicobacter Infections / drug therapy,  microbiology*
Helicobacter pylori / drug effects*,  genetics,  isolation & purification
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Point Mutation
Polymerase Chain Reaction
Rifabutin / pharmacology*
Rifampin / administration & dosage,  pharmacology
Treatment Failure
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 13292-46-1/Rifampin; 72559-06-9/Rifabutin; EC 2.7.7.6/DNA-Directed RNA Polymerases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Anthocyanin-rich Aronox extract from Aronia melanocarpa E protects against 7beta-hydroxycholesterol-...
Next Document:  Effect of oral glutamine on enterocyte turnover during methotrexate-induced mucositis in rats.